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Abstract
An alternative hypothesis has been proposed implicating chronic cerebrospinal venous insufficiency (CCSVI) as a potential
cause of multiple sclerosis (MS). We aimed to evaluate the validity of this hypothesis in a controlled animal model. Animal
experiments were approved by the institutional animal care committee. The jugular veins in SJL mice were ligated bilaterally
(n=20), and the mice were observed for up to six months after ligation. Sham-operated mice (n=15) and mice induced
with experimental autoimmune encephalomyelitis (n=8) were used as negative and positive controls, respectively. The
animals were evaluated using CT venography and
99mTc-exametazime to assess for structural and hemodynamic changes.
Imaging was performed to evaluate for signs of blood-brain barrier (BBB) breakdown and neuroinflammation. Flow
cytometry and histopathology were performed to assess inflammatory cell populations and demyelination. There were both
structural changes (stenosis, collaterals) in the jugular venous drainage and hemodynamic disturbances in the brain on
Tc99m-exametazime scintigraphy (p=0.024). In the JVL mice, gadolinium MRI and immunofluorescence imaging for barrier
molecules did not reveal evidence of BBB breakdown (p=0.58). Myeloperoxidase, matrix metalloproteinase, and protease
molecular imaging did not reveal signs of increased neuroinflammation (all p.0.05). Flow cytometry and histopathology
also did not reveal increase in inflammatory cell infiltration or population shifts. No evidence of demyelination was found,
and the mice remained without clinical signs. Despite the structural and hemodynamic changes, we did not identify
changes in the BBB permeability, neuroinflammation, demyelination, or clinical signs in the JVL group compared to the
sham group. Therefore, our murine model does not support CCSVI as a cause of demyelinating diseases such as multiple
sclerosis.
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Introduction
Multiple sclerosis (MS) is a chronic, inflammatory disease of the
central nervous system that affects over two million people
worldwide [1,2,3,4]. It is characterized by blood-brain barrier
breakdown, neuroinflammation, and demyelinating plaques.
However, the exact pathogenesis of MS is still unknown and
there is currently no known cure. Recently, a new hypothesis
implicating chronic cerebral venous insufficiency, coined chronic
cerebrospinal venous insufficiency (CCSVI), as the cause of MS
has gained widespread attention and interest from patients and
physicians [5,6]. There is an increasing number of studies linking
cerebral venous insufficiency to various neurologic diseases such as
transient global amnesia [7] and MS [6]. The idea of MS having a
vascular etiology was first introduced over a century ago by
Charcot who found thickening of small blood vessels in MS
patients [8], but other hypotheses (autoimmune, toxin, and virus)
are more commonly invoked as possible causes.
First described by Zamboni and co-workers, CCSVI is
characterized by impaired extracranial venous drainage, notably
in the internal jugular veins (IJVs), vertebral veins (VVs), and deep
cerebral veins (DCVs), and the formation of collateral vessels [6].
It has been proposed that CCSVI may lead to increased iron
deposition in the brain, leading to an inflammatory or immune
reaction and the formation of MS lesions [5,6,9,10,11]. Percuta-
neous transluminal angioplasty and stenting have emerged as
potential treatment options for MS patients as a result of this new
hypothesis [12]. However, the invasive nature of the procedure
can lead to serious complications, including stent migration,
cerebral hemorrhage, jugular vein thrombosis, and even death
[13]. Since the original study on CCSVI and its reported strong
association to MS, several other studies have not been able to show
a definitive confirmation of the CCSVI hypothesis for MS [14].
Given that there is no cure for MS and the current disease
modifying immunomodulatory therapies only help to slow the
disease progression, treatment of CCSVI could represent a
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Conversely, MS patients may be at risk from unnecessary
endovenous interventions if the validity of the CCSVI hypothesis
is ultimately disproven. To date, there has been no animal model of
CCSVI reported in the literature that investigates the relationship
between venous congestion arising from extracranial stenosis and
the development of demyelination. Thus, we aimed to investigate
this hypothesis in a controlled animal model by creating chronic
cerebral venous insufficiency in mice. We hypothesized that these
animals could exhibit the hallmarks of demyelinating diseases such
as MS, including clinical signs, blood-brain barrier (BBB)
breakdown, neuroinflammation, and demyelination.
Materials and Methods
Ethics statement
Ethical approval was obtained from the Institutional Animal
Care and use Committee of Massachusetts General Hospital
(Animal Welfare Assurance #A3596-01) in accordance with
national and international guidelines. Massachusetts General
Hospital maintains full accreditation from the Association for
Assessment and Accreditation of Laboratory Animal Care. All
experimental procedures were performed only with sedated
animals and appropriate analgesia was administered. Animal
welfare and steps were taken to ameliorate suffering in accordance
with the recommendations of the Weatherall report (2006).
Jugular vein ligation (JVL)
Forty-three mice were used for the study. Surgical ligation of the
right and left JVs was performed on female SJL mice (n=20) 8–12
weeks old (NCI-Frederick, Frederick, MD). Sham surgery
involving exposure of the JVs but no ligation was performed on
age and sex-matched SJL mice (n=15). Experimental autoim-
mune encephalomyelitis (EAE) was also induced in SJL mice as a
positive control (n=8). The SJL strain of mice was chosen because
it has been shown to have increased susceptibility to developing
inflammatory demyelination [15] seen in MS.
EAE induction
Female SJL mice 8–12 weeks old (NCI-Frederick, Frederick,
MD) were used with synthetic proteolipid protein (PLP139-151,
Anaspec, Fremont, CA) to induce EAE. One milligram of PLP
and 4 mg of M. tuberculosis H37Ra (Difco, Detroit, MI) were
dissolved in 0.5 ml of completed Freud’s adjuvant (Sigma-Aldrich,
St. Louis, MO). The content was emulsified using a high-speed
homogenizer for approximately two minutes on ice. Each mouse
received 100 ml of the PLP emulsion (25 ml each in the inguinal
and axillary regions bilaterally). On days 0 and 2, 0.1 mgo f
pertussingen (P7208, Sigma-Aldrich, St.Louis, MO) dissolved in
200 ml of phosphate-buffered solution was injected intravenously
via the tail vein.
Evaluation of neurological disease
The mice were monitored and weighed at least three times a
week, and were followed clinically using the standard 5-point EAE
staging system for 4–6 months post-surgery: 0=no signs,
1=complete tail limpness without limb weakness, 2=limb
weakness without obvious paralysis on ambulation, 3=one limb
with partial paralysis, 4=one limb with complete paralysis, and
5=moribund [16].
CT venogram and 3D reconstruction
CT venogram was performed on an animal CT scanner
(Siemens, Washington DC) in a subset of mice to confirm ligation
of JVs in the JVL group (n=6) and JV patency in the sham group
(n=3) at four months post-surgery to identify chronic structural
changes resulting from JV ligation. CT acquisition consisted of 360
cone beam x-ray projections over 360 degrees with a moving
source fixed to a slip-ring gantry. X-ray source power and current
were 80 keV and 500uA, respectively. Projections were then
reconstructed into three-dimensional isotropic volumes containing
51265126768 voxels, and a voxel dimension of 0.11060.1106
0.110 mm. During CT, mice were continuously injected with an
iodine contrast agent (Isovue-370, Bracco Diagnostics, Princeton,
NJ) at 20 uL/min for the 10-minute scan. 3D reconstruction was
performed on the contrast enhanced CT images using the Amira
software (San Diego, CA) by first segmenting out the bone via
thresholding, deleting the bone region-of-interest (ROIs), and
lastly, using region based thresholding on the unsegmented region
to segment out the vessels.
Magnetic resonance imaging
All chemicals were obtained from Sigma-Aldrich (St. Louis,
MO) except where indicated. DTPA-Gd (Magnevist) was obtained
from Berlex (Mountville, NJ). The myeloperoxidase (MPO)-
sensing MR imaging agent bis-5HT-DTPA(Gd) (MPO-Gd) was
synthesized as previously described [17,18]. Briefly, 100 mg
(0.28 mmol) of DTPA-bisanhydride was reacted with serotonin
(Alfa Aesar, Ward Hill, MA) in dimethylformamide (DMF [4 mL])
in the presence of 100 mL (1 mmol) of pyridine and 50 mg
(2.8 mmol) of ascorbic acid. The mixture was then stirred for
30 minutes at room temperature. The crude product was
subsequently precipitated with ether, dissolved in water and
passed through a C18 cartridge with water and acetonitrile
mixtures. The synthesis of corresponding Gd
3+ complexes was
performed in a 5% citric acid solution (pH=5.0) at room
temperature. GdCl3N6H2O was used in excess (1.5-fold) in
comparison to the chelates and the reaction was stirred for
1 hour. The final product was purified using high-performance
liquid chromatography and peaks were detected at 280 nm. The
purity of the agent was confirmed by mass spectrometry.
To evaluate whether our model causes cerebral inflammation,
we performed MPO-Gd molecular imaging to assess in vivo MPO
activity. MPO is a highly oxidizing enzyme secreted in abundance
by activated neutrophils, macrophages, and microglia in inflam-
mation, and MPO-Gd is an activatable MR imaging agent that
can report MPO activity in vivo with high specificity and
sensitivity [16,19,20,21]. MRI was performed on a subset of
JVL mice (n=12) and sham mice (n=4) between 4–6 months
post-surgery. Four of the JVL mice were also imaged at one month
after surgery. Additionally, we also imaged EAE mice (n=3) at
peak acute disease (day 10). One JVL mouse was found to have a
small subdural hematoma, and was excluded from the study
because subdural hematoma is not a reported feature or outcome
of CCSVI or MS. Imaging was performed using a dedicated
mouse brain coil (model T8118) on an animal 4.7 T MRI scanner
(Bruker) consisting of T2- (TE=20.0 ms, effective TE=60.0 ms,
TR=2460 ms, 8 averages) and T1- (TE=8.480 ms,
TR=873 ms, 14 averages) weighted scans before and after
intravenous administration of MPO-Gd (0.3 mmol/kg). Post
contrast T1 images were obtained every 15 minutes for 60 min-
utes. Respiratory gating was used during all scans. DTPA-Gd
(0.3 mmol/kg) was imaged using a similar protocol as above
except only one post contrast T1 time point was acquired.
The images were analyzed using a house-built Matlab program,
which creates an MPO activity map of the brain. ROI’s were
manually created using the Amira software for the muscle
background and noise (outside of mouse image) and the brain
Jugular Vein Ligation and Demyelination in Mice
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were then used to calculate the activation ratio [21] on a voxel-by-
voxel basis utilizing muscle as background instead of normal-
appearing brain, which may contain subtle inflammation.
The MRI T1 gadolinium enhanced images were performed to
assess contrast agent extravasation as a marker for blood-brain
barrier (BBB) breakdown. Images were quantified by manually
segmenting out an ROI of normal brain and an area outside the
boundaries of the mouse for noise. An automatic segmentation
algorithm was used to segment out the brain in utilizing Matlab,
which finds the largest connected region in the head. Contrast-to-
noise ratios of the post-Gd images was found by taking the mean
value over the whole brain minus the mean normal brain
background and dividing by the standard deviation of the noise.
Nuclear scintigraphy
Some mice in the JVL group (n=4) and sham group (n=4)
were injected with approximately 250 uCi of technetium-99 m
(half life=6.03 hours) labeled exametazime (Ceretec, GE Health-
care, Waltham, MA.) at 4 months post-surgery to assess
hemodynamic changes from the JVL. Thirty minutes after
injection, the mice were sacrificed, perfused with 20 ml of ice-
cold saline, and the brain was excised and the radioactivity
counted on a Wallac Wizard 1480 automatic gamma counter
(Perkin-Elmer, Waltham, MA).
The gamma counter data was decay corrected back to the time
of animal sacrifice. The percent injected dose per gram of tissue
(%IDGT) was calculated for each brain, representing the
measured tissue scintigraphy count as a percentage of amount
(gram) of brain tissue and injected dose (i.e. normalized to correct
for tissue mass and injected dose).
Fluorescence molecular tomography (FMT)-CT Imaging
We also performed FMT-CT in a subset of mice at 6 months of
age (n=3 sham, n=3 JVL mice) to assess whether matrix
metalloproteinase (MMP)andproteaseactivities, whicharemarkers
for BBB breakdown and inflammation [22,23], are elevated in the
JVL mice. Twenty-four hours prior to imaging mice received an
intravenous injection of 2 fluorescent imaging agents
(MMPSense680 and ProSense750, 2 nmol per agent, PerkinElmer,
Waltham, MA). MMPSense680 is an activatable fluorescent probe
that can detect matrix metalloproteinase (MMP) activity, in
particular MMP-2, -3, -9, and -13. ProSense750 is a protease
activatable fluorescent probe that can detect cathepsin B, L, S, and
plasmin activity. Anesthetized micewere depilatedprior to imaging.
Mice were placed in the imaging cassette, which has been designed
with built-in fiducial markers (four holes filled with gel water for CT
and FMTto detect)for enhancedpost-processing image fusion [24].
FMT imaging was carried out on a commercial FMT2500 system
(PerkinElmer, Waltham MA). Total fluorescent signal, expressed in
picomole scale, were determined by placing regions of interest over
the mouse brain in the FMT-CT fused reconstructed scans.
Mice were then transferred to the CT scanner (Siemens,
Washington DC) in the cassette to undergo anatomical imaging
for spatial localization of the FMT signal. CT acquisition was
performed similarly as above for CT venogram.
Utilizing the fiducial markers on the mouse cassette, FMT and
CT datasets were fused to produce images showing both
fluorescent activity and anatomical structure. Coronal CT images
were point-based co-registered to the FMT datasets using OsiriX.
Isolation of brain inflammatory cells and flow cytometry
Inflammatory cell isolation. Mice were transcardially
perfused with 20 ml of ice-cold phosphate-buffered saline (PBS).
Extracted brains were stored in ice-cold Hanks’ balanced salt
solution (HBSS), containing 15 mM HEPES (N-2-
hydroxyethylpiperazine-N9-2-ethanesulfonic acid) and 0.5%
glucose. Brain tissue was mechanically dissociated in a loose-
fitting glass tissue homogenizer in 5 ml of ice-cold HBSS. After
homogenization, the cell suspension was filtered through a 40-mm
cell strainer (BD Bioscience, San Jose, CA) into 50 ml conical
tubes, and washed with 15 ml ice-cold HBSS. Finally, cells were
pelleted at 5006 g for 10 min at 4uC, the supernatant was
discarded, and cells were resuspended in 10 ml 30% Percoll (17-
0891-01, GE Healthcare, Boston, MA) at room temperature. The
resultant cell suspension was gently overlaid over 3 ml 70% Percoll
in a 15 ml conical tube, so that a sharp interface between the two
layers was visible [25]. The density gradient was then centrifuged
in a swinging bucket rotor at 8006 g for 25 min at room
temperature, without brakes applied. After centrifugation, a thick
myelin-containing layer at the top was removed and the cells at the
30/70 interface were collected. The suspension was then diluted at
least threefold with ice-cold Dulbecco’s PBS (DPBS), centrifuged
at 5006g for 10 min at 4uC, and resuspended using 1 ml staining
buffer (1% FBS and 0.5% BSA in DPBS). The cells were then
counted and stained for flow cytometry.
Flow cytometry. The following antibodies (all from BD
Bioscience unless stated otherwise) were used: anti-CD90-PE, 53-
2.1; anti-NK1.1-PE, PK136; Anti B220-PE, RA3-6B2; anti-
CD49b-PE, DX5; anti-Ly-6G-PE, IA8; anti-CD45.1-APC, A20;
anti-CD11b-APC-Cy7, M1/70; anti-F4/80-Biotin, C1:A3-1
(BioLegend, San Diego, CA); and anti-CD11c-Biotin, HL3).
Streptavidin-PerCP was used to label biotinylated antibodies.
Lineage antibodies (Lin), consisting of CD90, NK1.1, B220,
CD49b, and Ly-6G were chosen based on work performed by
Swirski and colleagues [26]. CD90 was used as a pan-T-cell
marker, NK1.1 for natural killer cells, B220 for B-cells, CD49b for
any remaining natural killer or T-cells not positive for CD90, and
Ly-6G as a specific marker for granulocytes. The importance for
CD49b in EAE has been shown in a recent study [27].
Doublets were excluded on an SSC-height versus SSC-width
plot, and all leukocytes were then identified as CD45.1+. Myeloid
cells were identified as CD11b
+ Lin
2 cells. Neutrophils were
CD11b
+ Lin
+, and Lymphocytes were CD11b
2 Lin
+. Myeloid
cells were further divided into macrophages/microglia (F4/80
high
CD11c
6) and monocytes (F4/80
2/low CD11c
2). Although there
are early reports of F4/80 positive monocytes in the literature,
flow cytometry can differentiate between high expression of F4/80
in macrophages/microglia versus low or even absent expression in
monocytes. This was recently demonstrated for monocytes from
spleen, blood, and bone marrow [26]. The total number of cells
was determined under a microscope with a hemocytometer
(Reichert, Buffalo, NY) according to manufacturer’s instructions.
Data were acquired on an LSRII (BD Biosciences) and analyzed
with FlowJo 9.3.2 (Tree Star, Inc., Ashland, OR).
Histopathological analysis
Following MR imaging, mice were sacrificed and the brains
were harvested for histopathological analysis. The brains were
embedded in optimal cutting temperature (O.C.T) compound
(Sakura Finetek, Torrance, CA) with isopentane on dry ice. Serial
6 micron thick fresh-frozen sections were prepared for histopath-
ological analysis. All the histological images were captured using a
digital slide scanner, NanoZoomer 2.0RS (Hamamatsu, Japan).
Immunohistochemical analysis. Brain tissue sections were
briefly treated with 0.3% hydrogen peroxidase solution prior to
incubating with rat anti-mouse Mac-3 antibody (BD Biosciences,
San Diego, CA) and rabbit polyclonal myeloperoxidase (MPO)
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secondary antibodies (biotinylated anti-rat IgG and biotinylated
anti-rabbit IgG)(Vector Laboratories, Burlingame, CA) were
applied respectively, and an avidin-biotin complex (ABC) kit
(Vector Laboratories, Burlingame, CA) and a 3-amino-9-
ethylcarbazole (AEC) substrate (DakoCytomation, Carpinteria,
CA), which produces a red end-product in the presence of
peroxidase, were used for the color development. All sections were
counterstained with Harris hematoxylin solution and a coverslip
was applied using an aqueous mounting medium.
Detection of demyelination. Luxol fast blue (LFB) staining
was performed using the luxol fast blue-cresyl echt violet stain
kit (DBS). The brain sections were incubated in luxol fast blue
stain solution at room temperature for 24 hours and
differentiated in 0.05% lithium carbonate solution, followed by
70% ethyl alcohol until gray and white matter was clearly
defined. The sections were counterstained with 0.1% cresyl echt
violet stain solution, dehydrated, and mounted with a
permanent mounting medium.
Immunofluorescence microscopy. Fresh-frozen brain
sections (adjacent sections from immunohistochemistry) were
incubated with rat anti-mouse CD31 antibody (PECAM-1, clone
MEC13.3, BD Biosciences, San Diego, CA), and either rabbit
polyclonal occludin antibody (Abcam, Cambridge, MA) or rabbit
polyclonal claudin-5 antibody (Abcam, Cambridge, MA).
Appropriate biotinylated secondary antibodies followed by
streptavidin-FITC (Vector Laboratories, Burlingame, CA) for
CD31, and streptavidin-DyLight594 (Vector Laboratories,
Burlingame, CA) for occludin and claudin-5 were applied. The
slides were coverslipped using a mounting medium with DAPI
(Vector Laboratories, Burlingame, CA) to identify the nuclei.
Images were captured and processed using an epifluorescence
microscope, Nikon Eclipse 80i (Nikon Instruments, Melville, NY),
with a Cascade Model 512B camera (Roper Scientific,
Martinsried, Germany).
Statistical Analysis
All results are reported as mean 6 standard error (SEM). The
data were tested for normality using the D’Agostino-Pearson
normality test and for equality of variances using the F test [28]. If
normality and equality of variances were not rejected at the 0.05
significance level, the group means were compared using the t-test.
Otherwise, for non-normally distributed data and/or the data with
unequal variances, we used the nonparametric Mann-Whitney U
test. A p-value less than 0.05 was considered to be statistically
significant. We used Graphpad Prism 5 for statistical analysis
(GraphPad Software, Inc., La Jolla, CA).
Results
Jugular vein ligation results in venous stenosis in vivo
with formation of collateral vessels
Five months after surgery, CT venograms showed normal,
widely patent jugular veins in sham mice (n=3; Fig. 1A). In
comparison, the CT venograms of the JVL group (n=6)
demonstrated severe stenosis of the jugular vein at the sites of
ligation (Fig. 1A and B). In addition, there was small collateral
vessel formation in the ligated group (yellow arrows in Fig. 1A and
B). These results confirm that jugular vein ligation resulted in
structural changes in the venous drainage.
Jugular vein ligation alters cerebral hemodynamics
After confirming successful bilateral JV ligation, we investigated
whether JVL resulted in altered cerebral hemodynamics. The JVL
group demonstrated significantly increased cerebral retention of
nuclear perfusion agent, Tc-99m-exametazime, compared to the
Figure 1. CT venogram and 3D vessel imaging of JV stenosis. (A) Sham mouse with patent JVs (white arrow). JVL mouse confirming ligation
of the right and left JV and formation of collateral veins (yellow arrow). (B) Sham mouse exhibits normal venous drainage. (C) Right-side view of JVL
mouse exhibits formation of small collateral vessels (yellow arrow) and stenosis due to surgical ligation (black arrow). Left-side view of JVL mouse
exhibits complete occlusion at ligation site (black arrow) with formation of collateral vessels (yellow arrow).
doi:10.1371/journal.pone.0033671.g001
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gram of tissue (%IDGT=7.0960.42 (sham) vs. 8.2960.11 (JVL),
p=0.024, Fig. S1) at 5 months post surgery. These results indicate
that bilateral jugular vein ligation altered cerebral hemodynamics
in the JVL group. Together with the structural abnormalities seen
on CT venograms, these results confirm that we have established a
mouse model of chronic cerebral venous insufficiency.
Chronic cerebral venous insufficiency in mice does not
result in blood-brain barrier breakdown or increased
MMP activity
As expected, gadolinium-enhanced MR imaging using DTPA-
Gd performed 4–6 months after surgery did not reveal any white
matter lesions or abnormal enhancement in the sham group.
However, we also did not detect any T2 hyperintense lesions or
abnormal enhancement in the JVL group. Quantification of MRI
data for increased parenchymal signal enhancement that would
indicate leakage of the contrast agent across the BBB showed no
statistically significant difference between the sham and JVL
groups (Fig. 2A), demonstrating that the BBB remained intact.
Furthermore, when we noninvasively assessed for MMP
activity, which can be related to BBB breakdown [22,23], we
again found no significant difference between sham and JVL mice
in the amount of the activated fluorescent probe detected, which
was minimal and could not be visualized (Fig. 3A). As a reference,
an inflammatory lesion would have 20–40 pmol of MMPsense
activity [29].
We also examined for subtle break down in the BBB by
assessing for the presence of the barrier molecules associated with
Figure 2. MR imaging to assess the blood-brain barrier and myeloperoxidase (MPO) activity. (A) MR imaging with DTPA-Gd does not
reveal changes in blood-brain barrier permeability. Sham group (n=3, CNR (contrast-to-noise ratio)=0.3260.17, JVL group (n=6, CNR=0.2160.051,
p=0.58). EAE data provided for comparison (n=3, 4.761.3, p=0.024 vs. JVL). (B) MPO activity map from MPO-Gd MRI to detect areas of
inflammation. A representative sham mouse (left) demonstrates no evidence of MPO activity. A representative JVL mouse (middle) demonstrates no
evidence of MPO activity. A stage 2 EAE mouse (right) for comparison.
doi:10.1371/journal.pone.0033671.g002
Figure 3. FMT-CT imaging of MMP and protease activity. (A) Representative images from sham and JVL mice show no visible signal from FMT
imaging. (B) Quantification of the fluorescence signal demonstrates barely measurable signal and no significant difference between sham and JVL
mice.
doi:10.1371/journal.pone.0033671.g003
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JVL mice sections demonstrated similar colocalization of these
molecules with the endothelium (CD31), consistent with an intact
BBB. On the other hand, EAE mice showed endothelial cells that
were not associated with these barrier molecules, revealing that
breakdown in the BBB had occurred.
Chronic cerebral venous insufficiency in mice does not
result in neuroinflammation or demyelination
We did not observe any evidence of increased MPO activity,
and thus inflammation in vivo in either the sham or the JVL
groups (Fig. 2B, compare to a representative EAE mouse with
stage 2 disease). We also imaged for protease (cathepsins) activity
on FMT-CT but again, did not find any significant difference
between sham and JVL mice (Fig. 3A, C), which demonstrated
minimal signal that could not be visualized (Fig. 3A). An
inflammatory focus has been found to exhibit 20–40 pmol of
activity [30].
We also wanted to identify if JVL caused immune cell
population shifts in the brain (Fig. 4). Similar to the imaging
results, there was no significant change in the number of
macrophages/microglia, monocytes, lymphocytes, and neutrophils
in the brains of sham and JVL mice, though all of these cells are
markedly increased in the brains of EAE mice. Together, these
findings show that JVL did not result in increased neuroinflamma-
tion.
Histopathological assays on sham and JVL mice at 5 months
post-ligation showed that both sham and JVL groups were devoid
of MPO-positive cells (Fig. 5A). Furthermore, we did not observe
macrophage/microglia infiltration, even though these are typically
present in human MS plaques as well as experimental murine
models of demyelinating disease (Fig. 5B). As the most important
hallmark of MS is demyelination, we could not find any evidence
of demyelination (Fig. 5C). Therefore, our results found no
evidence of either inflammatory cellular infiltrate or products of
inflammation in either the sham or the JVL groups to suggest
neuroinflammation or demyelination at the time of sacrifice.
Chronic cerebral venous insufficiency in mice does not
result in clinical signs
Mice were also followed longitudinally (6 months) for clinical
signs or disease progression using a 5-point EAE scoring system
Figure 4. Flow cytometric analysis of brain inflammatory cells. (A) Cells were pre-gated for positive CD45 expression to identify all
leukocytes, and (B) then divided into lymphocytes, neutrophils, and myeloid cells. The total number of all leukocytes, but also lymphocytes,
neutrophils, and myeloid cells in the brain was unaffected in JVL mice (n=4) compared to sham (n=4), but significantly increased in EAE mice (n=5).
(C) Differentiating macrophages/microglia from monocytes showed that there were almost no monocytes in the brain of JVL and sham mice, but
both cell types were increased to high numbers in EAE mice. Lin=CD90, NK1.1, B220, CD49b, and Ly-6G.
doi:10.1371/journal.pone.0033671.g004
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PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e33671[16]. None of the mice in the JVL group or sham group showed
any clinical signs (Fig. S3) throughout the duration of the study.
Both groups exhibited a steady increase in weight and did not
undergo the typical weight loss observed in diseased or impaired
mice (Fig. 6).
Discussion
In this study, we developed a murine model of chronic cerebral
venous insufficiency in order to evaluate the relationship between
CCSVI and demyelination. Our model consisted of bilateral JV
ligation to mirror the cerebral venous abnormalities previously
reported [6], including multiple stenoses, formation of the cervical
collateral venous drainage pathways similar to those described in
CCSVI [6], and cerebral hemodynamic disturbances. Despite
both structural and hemodynamic abnormalities in the JVL group
consistent with successful induction of chronic cerebral venous
insufficiency, we did not find any evidence of BBB breakdown,
neuroinflammation, or demyelination in the brain. For each
parameter of disease progression that we assessed, we consistently
found no difference between the sham and JVL groups. Our
findings suggest that even significant disturbances in JV hemody-
namics, such as those seen in this model, do not result in
neuroinflammation and/or demyelinating plaques.
While animal models are invaluable research tools in helping us
understand human disease, they are imperfect models. The human
circulation system differs from that of the mouse in both structure
and position. Since humans are bipeds and stand erect, the human
brain axis is aligned approximately 90 degrees more ventral than
the mouse brain with respect to the axis of the body. The exact
effect that this postural difference has, if any, on mouse cerebral
hemodynamics versus human cerebral hemodynamics is unclear.
Furthermore, it is possible that additional stress or stimuli might be
needed to increase cardiovascular demand in our animal model
since mice are more sedentary compared to humans. Both posture
and activity may therefore potentially play a role in exacerbating
the effects of venous congestion resulting from venous stenosis. To
address these possible confounding variables, we aimed to
maximize the resting state of venous pressure by surgically ligating
both JVs in order to create an extreme scenario of increased
Figure 5. Histopathology of sham (top row), JVL, (middle row), and EAE (bottom row) groups. (A) MPO stain for MPO-positive cells/
myeloid cells, (B) Mac-3 stain for activated macrophages/microglia, and (C) LFB stain for demyelination. Bar=50 mm.
doi:10.1371/journal.pone.0033671.g005
Figure 6. Weights of sham group (n=6, open circle) and JVL
group (n=16, solid square) up to day 130 post-surgery.
doi:10.1371/journal.pone.0033671.g006
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PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e33671venous cerebral venous insufficiency. Some studies have reported
that 91% of MS patients having either unilateral or bilateral JV
stenosis, with 14% exhibiting bilateral stenosis in the jugular veins
[6]. In this way, we believe we have accounted for possible
differences in cerebral venous hemodynamics between mice and
humans by creating a murine model with relatively greater
cerebral venous insufficiency than previous positive studies have
reported in humans [6]. The mice were followed for up to 6
months after JVL, a considerable part of the lifespan of SJL mice
(typically around 400 days) which, particularly given the
maximization of venous pressure by bilateral JVL, should be
more than sufficient for disease manifestation if there was a
relationship between venous congestion and demyelination.
Currently, the hypothesis that CCSVI causes MS is unproven
but remains highly attractive to many patients and physicians.
Conflicting results have been found in clinical trials. Our
longitudinal animal study evaluated for multiple fundamental
signs known to occur in MS in order to assess for a relationship
between chronic venous congestion and demyelination. We found
that chronic cerebral venous insufficiency in our animal model
does not cause BBB breakdown, neuroinflammation, demyelinat-
ing plaques, or clinical manifestations that are the hallmarks of a
demyelinating disease such as multiple sclerosis. Therefore, our
animal study does not support chronic cerebral venous insuffi-
ciency as a cause of multiple sclerosis.
Supporting Information
Figure S1 Gamma scintillation counter using Tc-99m-
exametazime. Sham group (n=4, %IDGT (% injected dose per
gram of tissue)=7.0960.42), JVL group (n=4, %IDGT=
8.2960.11), p=0.024.
(DOCX)
Figure S2 Double immunofluorescence to assess barri-
er molecules. (A) Claudin-5 and CD31 in jugular vein ligation
mice compared with sham and EAE mice. In areas of
neuroinflammation in EAE, as indicated by MPO immunohisto-
chemistry in adjacent sections (top row), there is a general paucity
of the barrier molecule claudin-5 (red), and there is a loss of co-
staining of claudin-5 with the endothelial cell marker CD31
(green, arrows). In jugular vein ligation and sham animals there is
no change in the staining pattern for claudin-5, and all vessels
show co-staining for CD31, demonstrating no alteration of the
blood-brain barrier. Cell nuclei are stained with DAPI (blue).
Black rectangles in top row show areas shown for immunofluo-
rescence. Similar findings were found for (B) occludin and CD31.
(DOCX)
Figure S3 EAE clinical scores of sham group (n=6, open
circle) and JVL group (n=16, closed square) up to day
130 post-surgery.
(DOCX)
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